Please assess the completion status of the following clinical trial:

Trial Title: The Fibrin Pad CV Phase III Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects ≥18 years of age, requiring an elective or urgent, open aortic surgical procedure utilizing cardiopulmonary bypass. Subjects in Japan between ≥18 and \<20 years of age will require consent by the subject's legal representative~* Subjects must be willing to participate in the study and provide written informed consent.~* Presence of an appropriate Target Bleeding Site (TBS) along the anastomotic suture line, involving a synthetic aortic graft, as identified intra-operatively by the investigator;~Exclusion Criteria:~* Subjects with known intolerance to blood products or to one of the components of the study product or unwilling to receive blood products;~* Exposure to another investigational drug or device in a clinical trial within 30 days prior to surgery or anticipated in the 60 day follow up period after surgery.~* Female subjects who are pregnant or nursing.~* TBS is from a large defects in visible arteries or veins where the injured vascular wall requires repair and maintenance of vessel patency or where there would be persistent exposure of EVARREST™ Fibrin Sealant Patch to blood flow and/or pressure during absorption of the product;~* TBS with major arterial bleeding requiring suture or mechanical ligation;~* TBS involves an expanded polytetrafluoroethylene (ePTFE) graft~* TBS within an actively infected field;~* Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine;~* Subjects with any intra-operative findings identified by the investigator that may preclude conduct of the study procedure;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EVARREST™ Fibrin Sealant Patch (Type: EXPERIMENTAL): EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
- Topical hemostat (Type: ACTIVE_COMPARATOR): Equine collagen with Human Fibrinogen and Human Thrombin

Based on this trial design, predict the completion outcome and termination type (if applicable).